These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17659486)

  • 41. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology.
    Nelson CP; Challiss RA
    Biochem Pharmacol; 2007 Mar; 73(6):737-51. PubMed ID: 17046719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ligand detection in the allosteric world.
    Kenakin TP
    J Biomol Screen; 2010 Feb; 15(2):119-30. PubMed ID: 20086210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allosteric modulation of G protein-coupled receptors.
    May LT; Leach K; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2007; 47():1-51. PubMed ID: 17009927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. I want a new drug: G-protein-coupled receptors in drug development.
    Schlyer S; Horuk R
    Drug Discov Today; 2006 Jun; 11(11-12):481-93. PubMed ID: 16713899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. G protein-coupled receptor dimers: functional consequences, disease states and drug targets.
    Dalrymple MB; Pfleger KD; Eidne KA
    Pharmacol Ther; 2008 Jun; 118(3):359-71. PubMed ID: 18486226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. G-protein-coupled receptor allosterism: the promise and the problem(s).
    Christopoulos A; May LT; Avlani VA; Sexton PM
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):873-7. PubMed ID: 15494038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors.
    Costa T; Cotecchia S
    Trends Pharmacol Sci; 2005 Dec; 26(12):618-24. PubMed ID: 16260046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening technologies for G protein-coupled receptors: from HTS to uHTS.
    De los Frailes M; Diez E
    Methods Mol Biol; 2009; 552():15-37. PubMed ID: 19513639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiplex GPCR assay in reverse transfection cell microarrays.
    Mishina YM; Wilson CJ; Bruett L; Smith JJ; Stoop-Myer C; Jong S; Amaral LP; Pedersen R; Lyman SK; Myer VE; Kreider BL; Thompson CM
    J Biomol Screen; 2004 Apr; 9(3):196-207. PubMed ID: 15140381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The apparent cooperativity of some GPCRs does not necessarily imply dimerization.
    Chabre M; Deterre P; Antonny B
    Trends Pharmacol Sci; 2009 Apr; 30(4):182-7. PubMed ID: 19269046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits.
    Suga H; Haga T
    Neurochem Int; 2007; 51(2-4):140-64. PubMed ID: 17659814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Orphan G protein-coupled receptors: from DNA to drug targets.
    Shaaban S; Benton B
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):535-47. PubMed ID: 12825450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors.
    Lohse MJ; Nikolaev VO; Hein P; Hoffmann C; Vilardaga JP; Bünemann M
    Trends Pharmacol Sci; 2008 Mar; 29(3):159-65. PubMed ID: 18262662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulating receptor function through RAMPs: can they represent drug targets in themselves?
    Sexton PM; Poyner DR; Simms J; Christopoulos A; Hay DL
    Drug Discov Today; 2009 Apr; 14(7-8):413-9. PubMed ID: 19150656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment.
    Raddatz R; Schaffhauser H; Marino MJ
    Biochem Pharmacol; 2007 Aug; 74(3):383-91. PubMed ID: 17572390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modeling small molecule-compound binding to G-protein-coupled receptors.
    Vaidehi N; Pease JE; Horuk R
    Methods Enzymol; 2009; 460():263-88. PubMed ID: 19446730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inverse agonism: more than reverting constitutively active receptor signaling.
    Dupré DJ; Rola-Pleszczynski M; Stanková J
    Biochem Cell Biol; 2004 Dec; 82(6):676-80. PubMed ID: 15674435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.
    Langmead CJ; Christopoulos A
    Trends Pharmacol Sci; 2006 Sep; 27(9):475-81. PubMed ID: 16889837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [G-protein-coupled receptors: general features and activation mechanisms].
    Bockaert J
    Bull Acad Natl Med; 2012 Dec; 196(9):1765-75. PubMed ID: 24552100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orphan GPCRs and their ligands.
    Civelli O; Saito Y; Wang Z; Nothacker HP; Reinscheid RK
    Pharmacol Ther; 2006 Jun; 110(3):525-32. PubMed ID: 16289308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.